Brief: Compass Therapeutics Reports Q3 Loss Per Share $0.10
12/11/2021 13:34
Nov 12 (Reuters) - Compass Therapeutics, Inc. CMPX.PK :
* COMPASS THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* Q3 LOSS PER SHARE $0.10
* CASH AND CASH EQUIVALENTS WITH PUBLIC OFFERING PROCEEDS TO
FUND
OPERATING EXPENSES, CAPITAL EXPENDITURES INTO Q4 2024
Source text for Eikon: ID:nBw5ld81Qa
Further company coverage: CMPX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback